Future studies should clarify whether FGF23 is merely a disease severity marker or a contributor to adverse outcomes in type 2 diabetes and establish whether antidiabetic medication can modify blood FGF23 levels. The gene discussed is FGF23; the disease is type 2 diabetes mellitus.